Korro Bio Inc. (NASDAQ:KRRO) shares are up on Friday as the company reported its fourth-quarter and full-year financial results, highlighting significant developments in its RNA editing platform.
Korro Bio reported a net loss of $117.3 million for the year ended December 31, 2025, compared to a loss of $83.6 million in the previous year, driven by non-cash impairment charges.
The company also noted a cash position of $85.2 million as of December 31, 2025, which it expects to sustain operations into the second half of 2028.
In addition, collaboration revenue increased to $6.4 million for 2025, up from $2.3 million in 2024, reflecting the impact of its research agreement with Novo Nordisk A/S (NYSE:NVO).
Tumultuous 2025 For Korro
Chardan Research wrote that 2025 was a tumultuous year for Korro.
After building momentum from June to October, the company suffered a considerable setback in November when it